Versanis Bio
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.
Domain
versanisbio.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$70.0M
Founded
2020
Tech Stack (8 technologies)
Frequently Asked Questions
What technologies does Versanis Bio use?+
Versanis Bio uses 8 technologies including Adobe Client Data Layer, Adobe Experience Manager Franklin, Adobe Experience Platform Launch.
What industry is Versanis Bio in?+
Versanis Bio operates in the Biotechnology industry.
Where is Versanis Bio based?+
Versanis Bio is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026